Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA is strategically focused on developing innovative therapies for neurodegenerative diseases, particularly through its robust pipeline that includes notable candidates like ACI-7104.056, which has already shown a significant increase in antibodies against pathogenic variants of aSyn, reflecting the potential for efficacy in future readouts. Additionally, the company's NLRP3 program, leveraging a highly BBB-penetrant molecule, could see heightened interest following the outcomes of the upcoming EVOKE trial, positioning AC Immune favorably within a growing market for Alzheimer's disease treatment solutions.

Bears say

AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, highlighting ongoing financial challenges as it invests heavily in clinical development. The company navigates significant risks common in the biopharmaceutical industry, such as unexpected clinical readouts and regulatory uncertainties, which could adversely impact its prospects. Furthermore, the complexity and price sensitivity of commercial markets for its product candidates could hinder potential revenue generation and overall financial stability.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.